Moderna Therapeutics, Inc.
Formerly MT NewCo, Inc.
Moderna Therapeutics, Inc. is listed today as Moderna, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2016 | $451 M | No. 1 | $250 million to $1 billion | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Moderna, Inc., its revenue in fiscal 2025 came from these product and service lines: Net product sales $1.82 billion (94%), COVID $1.81 billion (93%), Other revenue $126 million (6%), Stand-ready manufacturing revenue $80 million (4%), Grant revenue $22 million (1%).
Annual report (SEC XBRL) · Dec 2025
Moderna Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2016).
SEC Form D · Aug 2016
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2016
Products#
- mRNA-1273 vaccine
From the company page of Moderna, Inc..
Services#
No services of Moderna Therapeutics, Inc. are on record.
Investors#
11 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Elizabeth G. Nabel | Person | not stated | not stated | Held Series G preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Flagship Pioneering, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship VentureLabs IV, LLC | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV General Partner LLC | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV-Rx, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Israel Ruiz | Person | not stated | not stated | Held Series G preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Lorence H. Kim | Person | not stated | not stated | Held Series E preferred stock (Form 3, 2018) | SEC Form 3 |
| Robert Langer | Person | not stated | not stated | Held Series G preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Stephen Berenson | Person | not stated | not stated | Held Series G preferred stock, director (Form 3, 2018) | SEC Form 3 |
| Stephen Hoge | Person | not stated | not stated | Held Series E preferred stock (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 72 investors.
Largest shareholders today
Institutions holding Moderna, Inc. shares, as of Sep 30, 2026.
- FMR LLC$11.4 B14.57%
- BlackRock, Inc.$5.4 B6.87%
- Vanguard Capital Management LLC$4.6 B5.91%
- Capital World Investors$4.4 B5.60%
- Vanguard Portfolio Management LLC$3.0 B3.90%
- State Street Corp$3.0 B3.82%
- Baillie Gifford & Co$2.2 B2.83%
- Geode Capital Management, LLC$2.0 B2.53%
- Price T Rowe Associates Inc /MD/$1.5 B1.88%
- Theleme Partners LLP$1.3 B1.65%
- Morgan Stanley$1.2 B1.49%
- Goldman Sachs Group Inc$1.1 B1.47%
- UBS Group AG$969 M1.24%
- Flagship Pioneering, LLC$892 M1.14%
- BNP Paribas Financial Markets$770 M0.99%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| James R. Kasinger | Executive officer | Aug 2016 |
| Lorence Kim | Executive officer | Aug 2016 |
| Stephane Bancel | Executive officer | Aug 2016 |
| Stephen Hoge | Executive officer | Aug 2016 |
| Elizabeth Nabel | Director | Aug 2016 |
| Henri Termeer | Director | Aug 2016 |
| John Mendlein | Director | Aug 2016 |
| Lee Babiss | Director | Aug 2016 |
| Noubar Afeyan | Director | Aug 2016 |
| Peter Hutt | Director | Aug 2016 |
| Robert Langer | Director | Aug 2016 |
| Stephane Bancel | Director | Aug 2016 |
About
American biotechnology company.
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.